MDWD Projected Dividend Yield

Ord/Mediwound Ltd. ( NASDAQ : MDWD )

Mediwound is a biopharmaceutical company focused on developing, manufacturing and commercializing bio- therapeutic solutions for tissue repair and regeneration. Co.'s primary biopharmaceutical product, NexoBrid, is used for the removal of dead or damaged tissue, known as eschar, in adults with deep partial-thickness and full-thickness thermal burns, also referred to as severe burns. Co.'s second product candidate, EscharEx, is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds. Co.'s third product candidate, MW005, is a topically applied biological drug candidate for the treatment of non-melanoma skin cancers.

20 YEAR PERFORMANCE RESULTS